慢性阻塞性肺疾病寒饮蕴肺证大鼠模型肺组织AQP1、Muc5ac表达的动态研究
|
摘要
目的:根据前期的研究基础，对慢性阻塞性肺疾病(chronic obstructivepulmonary disease，COPD)及寒饮蕴肺证理论进行简要的梳理和论述，以肺组织中水通道蛋白AQP1及黏蛋白Muc5ac为切入点，进一步探讨COPD寒饮蕴肺证病机的动态演变与水通道蛋白AQP1及黏蛋白Muc5ac的关系，以丰富寒饮蕴肺证理论。本题延续采用寒凉刺激结合烟熏及气管内滴注内毒素（LPS）的方法建立COPD寒饮蕴肺证的病证结合大鼠模型，通过观察模型大鼠60天的自然演变过程及自拟温阳化饮方、布地奈德干预下的病机演变过程，阐释COPD寒饮蕴肺证模型大鼠肺组织水通道蛋白AQP1、黏蛋白Muc5ac、肺功能、肺组织形态学的动态变化（以10天为一个阶段），以及自拟温阳化饮方对COPD寒饮蕴肺证模型大鼠肺组织水通道蛋白AQP1、黏蛋白Muc5ac的调节作用，确定自拟温阳化饮方的作用靶点及时效，为该病证的防治提供新思路和理论支撑，指导预防措施的制定以及治疗时机选择和疗程的确定。
方法:采用烟熏及气管内滴注LPS，配以寒凉刺激（0℃冰箱中冷冻，冰水混合物饮用）复制出COPD寒饮蕴肺证病证结合模型，动态观察（间隔10天，共60天）该大鼠模型的自然状态下的病机演变，并用自拟温阳化饮方和布地奈德对该病证模型进行动态干预，观察模型大鼠的一般情况，肺组织病理学，检测有关肺功能指标，肺组织中水通道蛋白AQP1，黏蛋白Muc5ac。
结果:本题以前期规范性的程序复制出可靠的COPD寒饮蕴肺证大鼠模型，模型大鼠的形态及行为的表现、指标的变化与COPD寒饮蕴肺证的临床表现相符。造模后大鼠吸气阻力和呼气阻力升高、肺顺应性下降，肺组织中水通道蛋白AQP1表达降低，黏蛋白Muc5ac表达升高，病理切片显示肺组织出现炎性损伤和肺纤维化改变。在撤除造模因素后60天内，随着病程的延长模型大鼠的症状及各项指标没有明显好转，且出现恶化，在40天左右寒饮蕴肺证的表现弱化，有转变为其他证型的趋势。自拟温阳化饮方干预的模型大鼠症状逐渐好转，肺功能改善，水通道蛋白AQP1表达升高，黏蛋白Muc5ac表达降低，病理切片示炎性损伤明显减轻，在40天左右达到峰值，接近正常大鼠水平。布地奈德干预下的模型大鼠症状也有好转，但水通道蛋白AQP1表达升高不明显，黏蛋白Muc5ac也无明显降低，病理切片示炎性损伤减轻。
结论:寒凉刺激结合烟熏和气管内滴注LPS建立的COPD寒饮蕴肺证大鼠模型是符合临床实际的理想的病证结合动物模型，具有良好的可靠性和稳定性。痰饮的形成是COPD寒饮蕴肺证病机演变的关键，水通道蛋白AQP1表达降低，黏蛋白Muc5ac表达升高与痰饮的形成关系密切。寒饮蕴肺证可能是COPD的早期或急性期证型，自拟温阳化饮方能够上调肺组织中水通道蛋白AQP1的表达和下调黏蛋白Muc5ac的表达，消除痰饮，对COPD寒饮蕴肺证有肯定的疗效，并且对该病证的治疗存在时效性，水通道蛋白AQP1、黏蛋白Muc5ac是其作用靶点之一。
Objective: According to the previous basic research on chronic obstructivepulmonary disease (chronic obstructive pulmonary disease, COPD) and accumulation ofcold fluid in the lung syndrome theory, with AQP1water channel protein in lung tissue andmucin Muc5ac as the starting point,to further explore the COPD accumulation of cold fluidin the lung disease machine dynamic evolution and water channel AQP1and mucinMuc5ac relationship, in order to enrich the theory of accumulation of cold fluid in the lung.It continues by cold stimulation combined with smoking and intratracheal instillation oflipopolysaccharide (LPS) rat model with the method of COPD accumulation of cold fluidin the lung syndrome, evolution of pathogenesis of budesonide by observing the model rats60days of natural evolution and the warming drink, intervention, explains COPD colddrink lung syndrome model of rat lung tissue water channel protein AQP1, and mucinMuc5ac and pulmonary function, the corresponding lung histomorphology changes (10days for a stage), as well as the warming drink fabric water channel protein AQP1, andmucin Muc5ac role in the regulation of COPD accumulation of cold fluid in the lung ratmodel of Lung Group, determine the target and aging with warming drink side, to providenew ideas and theoretical support for the prevention and treatment of diseases, todetermine the guiding preventive measures and treatment timing and duration.
Methods: The model with the COPD syndrome of cold fluid retention in lungdisease copied out by smoking and intratracheal instillation of LPS accompanied by coldstimulation (0℃refrigerator freezer, ice and water mixture drinking),dynamicobserve(interval of10days,60days) the rat model of the natural state of evolution, and the disease model for dynamic intervention with warming drink and budesonide, observe thegeneral model of rat, pulmonary pathology, lung function testing related indicators, AQP1water channel protein in lung tissue, mucin Muc5ac.
Results: This program use preliminary normative to copy out the COPDaccumulation of cold fluid in the lung of rats model. Index form and behavior in model ratsof change and COPD accumulation of cold fluid in the lung syndrome are reliable toclinical manifestations. After modeling the inspiratory resistance and expiratory resistancerats increased, decreased lung compliance, water channel protein decreased expression ofAQP1in lung tissue, Muc5ac expression increased, pathology showed lung tissue changesin inflammatory injury and fibrosis. On the60day after removal of molding factors, alongwith the prolonged duration of symptoms and indexes of the model rats had no obviousimprovement, and deteriorated in40days or so, the weakening of accumulation of coldfluid in the lung syndrome, is transformed into the other card type trend. Rat model ofsymptoms by warming drink party intervention gradually improved, improve lung function,water channel protein AQP1expression increased, Muc5ac expression decreased, thepathological sections showed inflammatory injury was relieved, reached the peak at40days, close to the normal level in rats. Rat model of budesonide intervention symptomsalso improved, but the water channel protein AQP1expression did not increase remarkably,mucin Muc5ac has no obvious fdecrease, the pathological sections showed decreasedinflammatory injury.
Conclusion: Cold stimulation combined with smoking and intratracheal instillation ofLPS is the establishment of animal model combining with clinical practical ideals diseasesof COPD accumulation of cold fluid in the lung of rats model of has a good reliability andstability. This is critical for the formation of COPD accumulation of cold fluid in the lungsyndrome pathogenesis evolution, reduced expression of water channel protein AQP1,mucin Muc5ac expression increased with the close relationship between the formation ofphlegm. Accumulation of cold fluid in the lung syndrome might be COPD early or acutesyndromes, with warming drink to the expression of AQP1water channel protein in lungtissue up-regulation and down-regulation of the expression of mucin Muc5ac, eliminatingphlegm, has a definite effect on COPD accumulation of cold fluid in the lung syndrome,and treatment of the disease in aging water channel protein, AQP1, Muc5ac mucin is oneof its targets.
方法:采用烟熏及气管内滴注LPS，配以寒凉刺激（0℃冰箱中冷冻，冰水混合物饮用）复制出COPD寒饮蕴肺证病证结合模型，动态观察（间隔10天，共60天）该大鼠模型的自然状态下的病机演变，并用自拟温阳化饮方和布地奈德对该病证模型进行动态干预，观察模型大鼠的一般情况，肺组织病理学，检测有关肺功能指标，肺组织中水通道蛋白AQP1，黏蛋白Muc5ac。
结果:本题以前期规范性的程序复制出可靠的COPD寒饮蕴肺证大鼠模型，模型大鼠的形态及行为的表现、指标的变化与COPD寒饮蕴肺证的临床表现相符。造模后大鼠吸气阻力和呼气阻力升高、肺顺应性下降，肺组织中水通道蛋白AQP1表达降低，黏蛋白Muc5ac表达升高，病理切片显示肺组织出现炎性损伤和肺纤维化改变。在撤除造模因素后60天内，随着病程的延长模型大鼠的症状及各项指标没有明显好转，且出现恶化，在40天左右寒饮蕴肺证的表现弱化，有转变为其他证型的趋势。自拟温阳化饮方干预的模型大鼠症状逐渐好转，肺功能改善，水通道蛋白AQP1表达升高，黏蛋白Muc5ac表达降低，病理切片示炎性损伤明显减轻，在40天左右达到峰值，接近正常大鼠水平。布地奈德干预下的模型大鼠症状也有好转，但水通道蛋白AQP1表达升高不明显，黏蛋白Muc5ac也无明显降低，病理切片示炎性损伤减轻。
结论:寒凉刺激结合烟熏和气管内滴注LPS建立的COPD寒饮蕴肺证大鼠模型是符合临床实际的理想的病证结合动物模型，具有良好的可靠性和稳定性。痰饮的形成是COPD寒饮蕴肺证病机演变的关键，水通道蛋白AQP1表达降低，黏蛋白Muc5ac表达升高与痰饮的形成关系密切。寒饮蕴肺证可能是COPD的早期或急性期证型，自拟温阳化饮方能够上调肺组织中水通道蛋白AQP1的表达和下调黏蛋白Muc5ac的表达，消除痰饮，对COPD寒饮蕴肺证有肯定的疗效，并且对该病证的治疗存在时效性，水通道蛋白AQP1、黏蛋白Muc5ac是其作用靶点之一。
Objective: According to the previous basic research on chronic obstructivepulmonary disease (chronic obstructive pulmonary disease, COPD) and accumulation ofcold fluid in the lung syndrome theory, with AQP1water channel protein in lung tissue andmucin Muc5ac as the starting point,to further explore the COPD accumulation of cold fluidin the lung disease machine dynamic evolution and water channel AQP1and mucinMuc5ac relationship, in order to enrich the theory of accumulation of cold fluid in the lung.It continues by cold stimulation combined with smoking and intratracheal instillation oflipopolysaccharide (LPS) rat model with the method of COPD accumulation of cold fluidin the lung syndrome, evolution of pathogenesis of budesonide by observing the model rats60days of natural evolution and the warming drink, intervention, explains COPD colddrink lung syndrome model of rat lung tissue water channel protein AQP1, and mucinMuc5ac and pulmonary function, the corresponding lung histomorphology changes (10days for a stage), as well as the warming drink fabric water channel protein AQP1, andmucin Muc5ac role in the regulation of COPD accumulation of cold fluid in the lung ratmodel of Lung Group, determine the target and aging with warming drink side, to providenew ideas and theoretical support for the prevention and treatment of diseases, todetermine the guiding preventive measures and treatment timing and duration.
Methods: The model with the COPD syndrome of cold fluid retention in lungdisease copied out by smoking and intratracheal instillation of LPS accompanied by coldstimulation (0℃refrigerator freezer, ice and water mixture drinking),dynamicobserve(interval of10days,60days) the rat model of the natural state of evolution, and the disease model for dynamic intervention with warming drink and budesonide, observe thegeneral model of rat, pulmonary pathology, lung function testing related indicators, AQP1water channel protein in lung tissue, mucin Muc5ac.
Results: This program use preliminary normative to copy out the COPDaccumulation of cold fluid in the lung of rats model. Index form and behavior in model ratsof change and COPD accumulation of cold fluid in the lung syndrome are reliable toclinical manifestations. After modeling the inspiratory resistance and expiratory resistancerats increased, decreased lung compliance, water channel protein decreased expression ofAQP1in lung tissue, Muc5ac expression increased, pathology showed lung tissue changesin inflammatory injury and fibrosis. On the60day after removal of molding factors, alongwith the prolonged duration of symptoms and indexes of the model rats had no obviousimprovement, and deteriorated in40days or so, the weakening of accumulation of coldfluid in the lung syndrome, is transformed into the other card type trend. Rat model ofsymptoms by warming drink party intervention gradually improved, improve lung function,water channel protein AQP1expression increased, Muc5ac expression decreased, thepathological sections showed inflammatory injury was relieved, reached the peak at40days, close to the normal level in rats. Rat model of budesonide intervention symptomsalso improved, but the water channel protein AQP1expression did not increase remarkably,mucin Muc5ac has no obvious fdecrease, the pathological sections showed decreasedinflammatory injury.
Conclusion: Cold stimulation combined with smoking and intratracheal instillation ofLPS is the establishment of animal model combining with clinical practical ideals diseasesof COPD accumulation of cold fluid in the lung of rats model of has a good reliability andstability. This is critical for the formation of COPD accumulation of cold fluid in the lungsyndrome pathogenesis evolution, reduced expression of water channel protein AQP1,mucin Muc5ac expression increased with the close relationship between the formation ofphlegm. Accumulation of cold fluid in the lung syndrome might be COPD early or acutesyndromes, with warming drink to the expression of AQP1water channel protein in lungtissue up-regulation and down-regulation of the expression of mucin Muc5ac, eliminatingphlegm, has a definite effect on COPD accumulation of cold fluid in the lung syndrome,and treatment of the disease in aging water channel protein, AQP1, Muc5ac mucin is oneof its targets.
引文
[1] Lopez AD,Murray CC.The global burden of disease,1990—2020.Nat Med,1998,4(11):1241-1243
[2]单淑香,陈宝元.慢性阻塞性肺疾病流行病学研究进展[J].国外医学呼吸系统分册,2005,25（6）:440-442．
[3]程显声,李景周,张珍祥,等.“慢性阻塞性肺病、肺心病人群防治的研究”基线资料分析[J].中华结核和呼吸杂志,1998,21(12):749-752．
[4]刘升明,王小平,王大礼,等.广东部分地区慢性阻塞性肺疾病发病状况调查[J].中华医学杂志,2005,85（11）:747-752．
[5]马睿,程齐俭,姚迪,等.上海地区老年人慢性阻塞性肺部疾病的流行病学研究[J].上海第二医科大学学报,2005,25（5）:521-524．
[6]徐忠星,董宇莉,艾来提,等.塔克拉玛干沙漠地区慢性阻塞性肺疾病调查研究[J].中国慢性病预防与控制,2003,11（1）:36．
[7]单淑香,陈宝元.天津市农村地区慢性阻塞性肺疾病危险因素的研究[J].天津医科大学学报,2005,11（1）:113-116．
[8]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2007年修订版）[J].中华结核呼吸杂志,2007,30(1):1-22.
[9]冉丕鑫.不可忽视生物燃料在慢性阻塞性肺疾病发病中的作用［J］.中华结核和呼吸杂志,2010,33（4）:693-718.
[10]郭峰,胡国平,况九龙.慢性阻塞性肺疾病的遗传易感性研究进展［J］.中华结核和呼吸杂志,2010,33（4）:241-242.
[11] Eisner MD,Anthonisen N,Coultas D,et al.An official American thoracicsociety public policy statement:novel risk factors and the global burdenof choronic obstructive pulmonary disease［J］.Am J Respir Crit CareMed,2010,182（12）:693-718.
[12]徐永健.加强对吸烟人群慢性阻塞性肺疾病易患性差异及其原因的研究［J］.中华结核和呼吸杂志,2010,33（4）:243-244.
[13] John VG,Shizu H,Mark E,et al.Differential expression of tissue repairgenes in the pathogenesis of chronic obstructive pulmonary disease［J］.Am J Respir Crit Care Med,2010,181（36）:1329-1335
[14]余学庆，李建生，李历．慢性阻塞性肺疾病（COPD）中医证候分布规律的研究[J]．河南中医学院学报,2003,18（4）:44-46.
[15]王洪武.寒饮蕴肺证的理论研究及其辨证要点的临床调研[D].济南：山东中医药大学，2003．
[16]金亚明,丁元华.COPD中医辨证分型及临床相关性研究分析[J].辽宁中医药大学学报,2008,10（7）:69-70.
[17]王洪武,孙广仁.寒饮蕴肺证辨证要点临床调查.山西中医,2004,20（3）:41-43
[18]李克光主编.金匮要略讲义[M].上海:上海科学技术出版社,1985:85-86.
[19]清·李用粹.证治汇补[M].北京:中国中医药出版社,2008.
[20]灵枢经[M].北京:人民卫生出版社,1993:75,11,70.
[21]程林删定.新安医籍丛刊·圣济总录[M].安徽:安徽科学技术出版社,1992.
[22]闫治达.慢性支气管炎阻塞性肺气肿的中医辨治体会[J].天津中医学院学报,2000,19（1）:20．
[23]王国忠,胡驰雄,丁美群等.热喘平合剂治疗阻塞性肺病痰热证82例观察[J]．浙江中医杂志,1999,40（12）:753．
[24]汪翠红,丁爱国.从病理生理学角度探讨慢性阻塞性肺病的中医固本治疗[J].中医杂志,1999,40（12）:753．
[25]黄礼明.试论痰、瘀、虚与慢性阻塞性肺疾病辨治关系[J].贵阳中医学院学报,2000,22（1）:5.
[26]薛汉荣.中医论治慢性阻塞性肺病[J].江西中医学院学报,2004,16（6）:13.
[27]孙志佳.中医防止慢性阻塞性肺疾病的理论探讨[J].浙江中医杂志,2004,（12）:507．
[28]傅志红.洪广祥教授治肺系疾病探要[J].新中医.1999,31（1）:12.
[29]高雪.曲敬来.论“肺阳”与慢性咳喘病的关系[J].中医药学报,1998,（4）:4.
[30]要全保.慢阻肺从脾论治初探[J].中医研究,1999,12（6）:4.
[31]田正鉴,徐幼明,李亚清.慢性阻塞性肺疾病中医病机探微[J].湖北中医学院学报,2001,3（1）:29.
[32]李素云,吴其标.曹世宏教授论治慢性阻塞性肺疾病经验选粹[J].中医药学刊,2002,20（1）:28.
[33]傅曙华.慢性阻塞性肺疾病病因病机及治法探讨[J].湖南中医杂志,2003,19（4）:3.
[34]李建生.中医药治疗慢性阻塞性肺疾病研究的实践与若干思考[J].河南中医,2005,25（5）:13-15.
[35]余学庆,李建生,马龙等.慢性阻塞性肺疾病中医证侯文献分析[J].辽宁中医杂志,2006,33（7）:794-795.
[36]中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医证候诊断标准（2011版[J].中医杂志,2012,53（2）:177
[37]中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医诊疗指南(2011版)[J].中医杂志,2012,53(1):80-84.
[38]张葵,张培琴,陈昱江,等.参芪补肺汤对慢性阻塞性肺疾病稳定期肺气虚证患者肺功能的影响[J].中国实验方剂学杂志,2012,18(1):213-216.
[39]范翎翔,欧阳卫东,李波,等.黄芪对COPD患者肺功能改善作用的研究[J].海军医学杂志,2003,24(3):261-263.
[40]刘志刚,李泽庚,彭波,等.六味补气胶囊对肺气虚型慢性阻塞性肺疾病稳定期患者生活质量和肺功能的影响[J].安徽中医学院学报,2012,3(1):6-9.
[41]曹颖,何明.慢性阻塞性肺疾病稳定期脏虚与肺功能关系的临床观察[J].北京中医药大学学报:中医版,2011,18(2):15-17.
[42]徐升.黄芪建中汤治疗慢性阻塞性肺疾病稳定期30例[J].山东中医杂志,2011,30(3):163-164.
[43]何迎春.补中益气汤加减改善慢性阻塞性肺疾病患者稳定期生活质量的临床疗效观察[J].中华中医药学刊,2010,28(3):506-507.
[44]徐莺,王敏.补肺益肾汤治疗慢性阻塞性肺气肿稳定期40例[J].河南中医,2008,28(5):40-41.
[45]孙子凯,曹世宏,徐丽华,等.益肾固本法对慢性阻塞性肺疾病缓解期患者疗效观察[J].时珍国医国药,2007,18(12):2980-2982.
[46]李琳,张赛,舒莉莉.参蛤胶囊治疗慢性阻塞性肺疾病肺肾亏虚痰湿阻肺证35例[J].中医药导报,2011,17(12):45-46.
[47]高轶峰,崔红,刘宾娜.养阴清肺汤治疗老年慢性阻塞性肺气肿[J].中国实验方剂学杂志,2011,17(4):204-205.
[47]李继圣,李坤,肺胀从瘀论治[J].河南中医学院学报,2003,18(6):39.
[48]杨荣源,林燕凤,李际强.小青龙汤加减治疗慢性阻塞性肺病急性加重期临床观察[J].新中医,2009,41(1):43-44.
[49]李建生,李彬,余学庆,等.清热化痰方药治疗慢性阻塞性肺疾病急性加重期痰热壅肺证69例临床观察[J].中医杂志,2011,52(3):203-207.
[50]王爱东.痰热清注射液治疗慢性阻塞性肺疾病急性加重期72例疗效观察[J].医学理论与实践,2011,24(6):664.
[51]张利君.苏子降气汤合三子养亲汤加减治疗慢性阻塞性肺疾病临床疗效观察[J].新中医,2011,43(2):31-32.
[52]贾杰.针刺配合康复训练治疗慢性阻塞性肺病66例[J].陕西中医，2004，25(12)：1125-1127．
[53]张玲.益气扶正汤加针刺治疗慢性阻塞性肺病288例[J].陕西中医,2003,24(10):882-883．
[54]万文蓉.宣散方针灸治疗慢性阻塞性肺疾病36例临床研究[J].光明中医,2007,22(3):40-42．
[55]杨平,张艳玲,彭敏.培土生金针刺法对COPD缓解期患者生活质量的影[J]．辽宁中医药大学学报,2009,1(3):149-150．
[56]宋昱晨.穴位贴敷与卡介苗素注射治疗稳定期慢性阻塞性肺病的疗效和免疫指标对比观察[J].浙江中医杂志,2008,43(8):44l-442．
[57]王玲,李风森,杨卫江.穴位经皮给药对慢性阻塞性肺病患者肺功能影响的研究[J].辽宁中医杂志,2006,33(10):1232-1233．
[58]刘斌，李英姿．中药外敷治疗慢性阻塞性肺病300例[J]．福建中医药，2001，32(6)：25．
[59]姜明全,曹忠良,项志兵,等.参麦注射液合用雾化吸人鱼腥草注射液治疗慢性阻塞性肺病急性加重期疗效观察[J].上海中医药杂志,2006,40(5):11-12．
[60]黄大文,李英姿,刘斌.中药制剂经氧气雾化吸人治疗慢性阻塞性肺病疗效观察[J].陕西中医学院学报,2003,26(4):7-9．
[61]辛瑾琛,谈馨媛,林琳.砭石治疗慢性阻塞性肺疾病急性加蓖期临床研究[J]．中国中医药信息杂志,2008,15(8):14-15．
[62]谭韬,毕番,杨秀萍,等.呼吸气功疗法对慢性阻塞性肺疾病稳定期患者肺康复的疗效研究[J].贵阳中医学院学报,2007,29(6):34-35．
[63]王洪武,孙广仁.寒饮蕴肺证辨证要点临床调查.山西中医,2004,20（3）：41-43
[64]颜乾麟.中医病机理论研究的思考[J].同济大学学报(医学版),2007,28（5）：2
[65]高雪,曲敬来.论“肺阳”与慢性咳喘病的关系［J］.中医药学报,1998,(4):3－4．
[66]万文蓉,卢泰坤论阳虚痰瘀是慢性阻塞性肺疾病的基本病机［J］.中医药学刊，2005,23(9):1672．
[67] Sun SH,Tang WX,Liu C,et al.Effects of tumonecrosis factor alpha onproteolysis of respiratory muscles in rats with chronic obstructivepulmonary diseas[J].Zhonghua Jie He He Hu Xi Za Zhi,2007,30(3):186-191.
[68] Chung K F.Cytokines in chronic obstructive pulmonary disease[J].EurRespir J,2001,18:50-59.
[69] Zheng T,Zhu Z,Wang Z,et al. Inducible targeting of IL-13to the adultlung causes matrix metalloproteinase and cathepsin dependent emphysema[J]. J Clin Invest,2000,106(9):1081-1093.
[70]董三军,等.慢性阻塞性肺疾病稳定期血清白介素4及白介素13水平调查[J].中国误诊学杂志.2010,10(28):7048
[71] Kasaian MT,Miller DK.IL-13as a therapeutic target for respir-atorydisease[J]. Biochem Pharmacol,2008,76(2):147-155.
[72] SHIRAKAWA I,DEICHMANN KA,IZUHARA I,et al. Atopy and asthma:geneticvariants of IL-4and IL-13gene signaling[J].Immunol Today,2000,21:60-64.
[73]商燕,李强.白介素-13与支气管哮喘[J]．国外医学.生理、病理科学与临床分册，2001,3:192-194.
[74] ZHENG T,ZHU Z,WANG Z,et al.Inducible targeting of IL-13to the adult lungcauses matrix metalloproteinase-and cathepsin-dependent emphysema[J].JClin Invest2000,106:1081-1093.
[75] VENKAYYA R,LAM M,WILLKOM M,et al.The Th2lymphocyte products IL-4andIL-13rapidly induce airway hyperresponsiveness through direct effectson resident airway cells[J].Am J Respir Cell Mol Biol,2002,26:202-208.
[76] Kuperman D A, Huang X, Koth L L,et al. Direct effects of IL-13onepithelial cells cause airway hyperreactivity and mucus overproductionin asthma[J]. Nat Med,2002,8(8):885-889.
[77] Takanashi S,et al. Interleukin-10level in sputum is reducedbronchialasthma, COPD and in smokers[J].Eur Respir J,1999,14(2):309-314.
[78] Barnes PJ.Mechanisms in COPD: differences from asthma.Chest,2000,117:105
[79] Segura-Valdez L,Pardo A,Gaxiola M,et al. Upregulation ofgelatinases Aand B,collagenases1and2,and increased paren-chymal cell death in COPD.Chest,2000,117:684.
[80]郭瑞霞,张建敏等.基质金属蛋白酶及其抑制物在慢性阻塞性肺病治疗中的价值[J].中国现代医生,2009,47(26):23
[81]郭瑞,张红梅.COPD患者基质金属蛋白酶-9及其抑制物的表达和调控[J].新医学，2008,39（2）:134-136.
[82]戴丽,吴泰华.全反式维甲酸对COPD大鼠肺组织中基质金属蛋白酶-2,9表达的影响[J].内科急危重症杂志,2007,13(5):239-246.
[83]陈洲平,连亚军,夏建华,等.戊四氮点燃大鼠海马水通道蛋白4和水通道蛋白9的表达[J].郑州大学学报(医学版),2008,43(3):428-431.
[84]关方霞,关玉霞,杨波,等.星形胶质细胞形态学观察在高通量药物筛选水通道蛋白4抑制剂中的应用[J].郑州大学学报(医学版),2006,41(5):870-872.
[85] Verkman AS. Role of aquaporins in lung liquid physiology [J]. RespirPhysiol Neurobiol,2007,159(3):324-330.
[86] Rose MC.Mucins:structUre，function，and role in Pulmonary disease[J].AmJPhy si ol,1992，263:L413-L429
[87] Alimam MZ,Piazza FM,Selby DM,et al.Muc-5/5ac mucin messenger RNA andprotein expression is a marker of goblet cell metaplasia in murineairways[J].AmJ Respir Cell Mol Biol,2000,22(3):253-260
[88] Kirkham S,Sheehan JK,Knight D,el.Heterogeneity of airways mucus:variations in the amounts and glycoforms of the major oligomeric mucinsMUC5AC and MUC5B[J].Biochem J,2002,361(Pt3):537-546
[89]万云鹏,关键,丁晓倩. COPD大鼠肺组织中Muc5ac和IL-13的相关性研究[J].现代生物医学进展,2009,9(21):4089
[90]张蔚等.福莫特罗对哮喘小鼠气道杯状细胞增生及黏蛋白MUC5ac mRNA表达的影响[J].温州医学院学报,2010,40(3):
[91] Boer de ⅤⅤⅠ,Han CM,Schadewijk van A,et al.Expression of epidermalgrowth factors and their receptors in the bronchial epithelium ofsubjects with chronic obstructive pulmonary disease. American Journalof Clinical Pathology,2006,125(2):184-192
[92] Luo BL,Niu BC,Feng JT,et al. Downregulation of secretory leukocyteproteinase inhibitor in chronic obstructive pulmonary disease:the roleof TGF-beta1/smads signaling pathways.Arch Med Res,2008,5,39(4):388-396
[93]孙广仁等.温阳化饮方对寒饮蕴肺证家兔肺通气作用的机理研究[J].上海中医药大学学报,2001,15(1):40-42
[94]张庆祥等.温阳化饮方对哮喘病寒饮蕴肺证大鼠BALF中EOS的影响[J].中医药学刊,2006,24(8):1477-1478
[95]张庆祥等.温阳化饮方对哮喘病寒饮蕴肺证大鼠BALF中IL-4和IFN-γ的影响[J].中国中医基础医学杂志,2006,12(9):672-673
[96] Song Y L，Yang B X，Michael A M，et al. Role of ayuaporin water channelsin pleural fluid dynamics［J］. Am J PhysioL Cell Physiol，2000，279：1744-1750.
[97] Song YL,Yang BX. Michael AM,et al. Role of aquaporin water channels inpleural fluid dynamics[J]. Am J Physiol Cell Physiol，2000l.279:C1744
[98] Borok Z. Verkman AS. Lung edema clearance;20years of progress; invitedreview；role of aquaporin water channels in fluid transport in lung andairways[J].J Appli Physiol,2002.93(6):2199
[99]李波，陈东，王桂芳，等.水通道蛋白1345在内毒素性急性肺损伤小鼠肺组织中的表达[J].第二军医大学学报，2008,29(2):131-133
[100]丛培玮,尚冰,王哲,等.肺气虚模型大鼠肺、肾组织水液代谢相关性的机制研究[J].辽宁中医杂志,2012,39(2):357-359
[101]王晴,刘正娟,马乐,等.水通道蛋白－1在急性肺损伤中的表达及意义［J］.大连医科大学学报,2012,34(1):22-25．
[102]丁建中,张六通,李军川,等.水通道蛋白1、4、5在外燥小鼠肺表达的意义[J].时珍国医国药,2012,23(3):764-765
[103]许银姬,陈远彬,王丽丽,林琳.青天葵对内毒素致急性肺损伤大鼠肺水通道蛋白1和5表达的影响[J].中国中西医结合杂志,2010,30(8):861-865
[104]邓青南,周建龙,郭振辉.清气化痰汤对急性肺损伤小鼠水通道蛋白1表达的影响［J］.中国中医急症,2011,20（1）：77-79.
[105] Hattrup CL,Gendler SJ. Structure and function of the cell surface(tethered) mucins[J].Annu Rev Physiol,2008,70:431-457.
[106] Morcillo EJ, Cortijo J.Mucus and MUC in asthma [J].Curr Opin Pulm Med,2006,12(1):1-6.
[107] Rose MC. Mucins: structure, function, and role in pulmonary diseases[J].Am J Physiol,1992,263(4Pt1):413-429.
[108] MA R, WANG Y, CHENG G, et al. MUC5AC expression up-regulation gobletcell hyperplasia in the airway of patients with chronic obstructivepulmonary disease[J]. Chin Med Sci J,2005,20(3):181-184.
[109]袁兵,但齐琴,赵珊.丙烯醛致大鼠气管和肺损伤中内源性Muc5ac的表达变化[J].四川大学学报(医学版),2010,41(6):994-997.
[110] CARAMORI G, DI GREGORIO C, CARLSTEDT I. Mucin expression in peripheralairways of patients with chronic obstructive pulmonary disease [J].Histopathology,2004,45(5):477-484.
[111] BORCHERS M T, WERT S E, LEIKAUF G D. Acrolein-induced MUC5AC expressionin rat airways [J]. Am J Physiol,1998,274(4Pt1):L573-L581.
[112]李雯,徐永健,张珍祥.慢性阻塞性肺疾病患者气道上皮细胞阿米洛利敏感钠通道mRNA表达水平的研究[J].中华结核和呼吸杂志,2004,27(8):533-536.
[113]李雯,徐永健,魏华平.白介素-4和白介素-6在慢性阻塞性肺病肺组织中的表达[J].中国组织化学与细胞化学杂志,2001,10(4):425-428.
[114] SHAO M X, NAKANAGA T, NADEL J A. Cigarette smoke induces MUC5AC mucinoverproduction via tumor necrosis factor-alpha-converting enzyme inhuman airway epithelial(NCI-H292) cells [J]. Am J Physiol Lung Cell MolPhysiol,2004,287(2):L420-L427.
[115]毛翎,白春学,张敏,等.表皮生长因子受体和黏蛋白在慢性阻塞性肺疾病气道中的表达及意义[J].中华结核和呼吸杂志,2004,27(9):585-588.
[116]王明明,张六通,丁建中,等.外感温燥对BALB/c小鼠气道muc5ac表达的影响[J].时珍国医国药,2011,22(7):1751-1753.
[117]王同生,娄源杰,毛毅敏,孙玉霞. MUC5AC黏蛋白在哮喘大鼠肺组织的表达及红霉素的抗炎机制探讨[J].河南科技大学学报（医学版）,2007,25(1):11-13
[118]周勇,赵玮,宋康,等.椒枝软胶囊对哮喘大鼠Muc5ac mRNA表达的影响[J].中华中医药学刊,2012,30(5):1130-1132.
[119]徐传芹,朱述阳,陈景行,岳刚.罗格列酮对哮喘小鼠气道黏液高分泌的影响[J].实用医学杂志,2008,24(22):3836-3838.
[120]熊本强,李翔,李喜兵,等.水通道蛋白1对气道高反应大鼠粘液高分泌的影响[J].湖南师范大学学报（医学版）,2012,9(1):6-9
[2]单淑香,陈宝元.慢性阻塞性肺疾病流行病学研究进展[J].国外医学呼吸系统分册,2005,25（6）:440-442．
[3]程显声,李景周,张珍祥,等.“慢性阻塞性肺病、肺心病人群防治的研究”基线资料分析[J].中华结核和呼吸杂志,1998,21(12):749-752．
[4]刘升明,王小平,王大礼,等.广东部分地区慢性阻塞性肺疾病发病状况调查[J].中华医学杂志,2005,85（11）:747-752．
[5]马睿,程齐俭,姚迪,等.上海地区老年人慢性阻塞性肺部疾病的流行病学研究[J].上海第二医科大学学报,2005,25（5）:521-524．
[6]徐忠星,董宇莉,艾来提,等.塔克拉玛干沙漠地区慢性阻塞性肺疾病调查研究[J].中国慢性病预防与控制,2003,11（1）:36．
[7]单淑香,陈宝元.天津市农村地区慢性阻塞性肺疾病危险因素的研究[J].天津医科大学学报,2005,11（1）:113-116．
[8]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2007年修订版）[J].中华结核呼吸杂志,2007,30(1):1-22.
[9]冉丕鑫.不可忽视生物燃料在慢性阻塞性肺疾病发病中的作用［J］.中华结核和呼吸杂志,2010,33（4）:693-718.
[10]郭峰,胡国平,况九龙.慢性阻塞性肺疾病的遗传易感性研究进展［J］.中华结核和呼吸杂志,2010,33（4）:241-242.
[11] Eisner MD,Anthonisen N,Coultas D,et al.An official American thoracicsociety public policy statement:novel risk factors and the global burdenof choronic obstructive pulmonary disease［J］.Am J Respir Crit CareMed,2010,182（12）:693-718.
[12]徐永健.加强对吸烟人群慢性阻塞性肺疾病易患性差异及其原因的研究［J］.中华结核和呼吸杂志,2010,33（4）:243-244.
[13] John VG,Shizu H,Mark E,et al.Differential expression of tissue repairgenes in the pathogenesis of chronic obstructive pulmonary disease［J］.Am J Respir Crit Care Med,2010,181（36）:1329-1335
[14]余学庆，李建生，李历．慢性阻塞性肺疾病（COPD）中医证候分布规律的研究[J]．河南中医学院学报,2003,18（4）:44-46.
[15]王洪武.寒饮蕴肺证的理论研究及其辨证要点的临床调研[D].济南：山东中医药大学，2003．
[16]金亚明,丁元华.COPD中医辨证分型及临床相关性研究分析[J].辽宁中医药大学学报,2008,10（7）:69-70.
[17]王洪武,孙广仁.寒饮蕴肺证辨证要点临床调查.山西中医,2004,20（3）:41-43
[18]李克光主编.金匮要略讲义[M].上海:上海科学技术出版社,1985:85-86.
[19]清·李用粹.证治汇补[M].北京:中国中医药出版社,2008.
[20]灵枢经[M].北京:人民卫生出版社,1993:75,11,70.
[21]程林删定.新安医籍丛刊·圣济总录[M].安徽:安徽科学技术出版社,1992.
[22]闫治达.慢性支气管炎阻塞性肺气肿的中医辨治体会[J].天津中医学院学报,2000,19（1）:20．
[23]王国忠,胡驰雄,丁美群等.热喘平合剂治疗阻塞性肺病痰热证82例观察[J]．浙江中医杂志,1999,40（12）:753．
[24]汪翠红,丁爱国.从病理生理学角度探讨慢性阻塞性肺病的中医固本治疗[J].中医杂志,1999,40（12）:753．
[25]黄礼明.试论痰、瘀、虚与慢性阻塞性肺疾病辨治关系[J].贵阳中医学院学报,2000,22（1）:5.
[26]薛汉荣.中医论治慢性阻塞性肺病[J].江西中医学院学报,2004,16（6）:13.
[27]孙志佳.中医防止慢性阻塞性肺疾病的理论探讨[J].浙江中医杂志,2004,（12）:507．
[28]傅志红.洪广祥教授治肺系疾病探要[J].新中医.1999,31（1）:12.
[29]高雪.曲敬来.论“肺阳”与慢性咳喘病的关系[J].中医药学报,1998,（4）:4.
[30]要全保.慢阻肺从脾论治初探[J].中医研究,1999,12（6）:4.
[31]田正鉴,徐幼明,李亚清.慢性阻塞性肺疾病中医病机探微[J].湖北中医学院学报,2001,3（1）:29.
[32]李素云,吴其标.曹世宏教授论治慢性阻塞性肺疾病经验选粹[J].中医药学刊,2002,20（1）:28.
[33]傅曙华.慢性阻塞性肺疾病病因病机及治法探讨[J].湖南中医杂志,2003,19（4）:3.
[34]李建生.中医药治疗慢性阻塞性肺疾病研究的实践与若干思考[J].河南中医,2005,25（5）:13-15.
[35]余学庆,李建生,马龙等.慢性阻塞性肺疾病中医证侯文献分析[J].辽宁中医杂志,2006,33（7）:794-795.
[36]中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医证候诊断标准（2011版[J].中医杂志,2012,53（2）:177
[37]中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医诊疗指南(2011版)[J].中医杂志,2012,53(1):80-84.
[38]张葵,张培琴,陈昱江,等.参芪补肺汤对慢性阻塞性肺疾病稳定期肺气虚证患者肺功能的影响[J].中国实验方剂学杂志,2012,18(1):213-216.
[39]范翎翔,欧阳卫东,李波,等.黄芪对COPD患者肺功能改善作用的研究[J].海军医学杂志,2003,24(3):261-263.
[40]刘志刚,李泽庚,彭波,等.六味补气胶囊对肺气虚型慢性阻塞性肺疾病稳定期患者生活质量和肺功能的影响[J].安徽中医学院学报,2012,3(1):6-9.
[41]曹颖,何明.慢性阻塞性肺疾病稳定期脏虚与肺功能关系的临床观察[J].北京中医药大学学报:中医版,2011,18(2):15-17.
[42]徐升.黄芪建中汤治疗慢性阻塞性肺疾病稳定期30例[J].山东中医杂志,2011,30(3):163-164.
[43]何迎春.补中益气汤加减改善慢性阻塞性肺疾病患者稳定期生活质量的临床疗效观察[J].中华中医药学刊,2010,28(3):506-507.
[44]徐莺,王敏.补肺益肾汤治疗慢性阻塞性肺气肿稳定期40例[J].河南中医,2008,28(5):40-41.
[45]孙子凯,曹世宏,徐丽华,等.益肾固本法对慢性阻塞性肺疾病缓解期患者疗效观察[J].时珍国医国药,2007,18(12):2980-2982.
[46]李琳,张赛,舒莉莉.参蛤胶囊治疗慢性阻塞性肺疾病肺肾亏虚痰湿阻肺证35例[J].中医药导报,2011,17(12):45-46.
[47]高轶峰,崔红,刘宾娜.养阴清肺汤治疗老年慢性阻塞性肺气肿[J].中国实验方剂学杂志,2011,17(4):204-205.
[47]李继圣,李坤,肺胀从瘀论治[J].河南中医学院学报,2003,18(6):39.
[48]杨荣源,林燕凤,李际强.小青龙汤加减治疗慢性阻塞性肺病急性加重期临床观察[J].新中医,2009,41(1):43-44.
[49]李建生,李彬,余学庆,等.清热化痰方药治疗慢性阻塞性肺疾病急性加重期痰热壅肺证69例临床观察[J].中医杂志,2011,52(3):203-207.
[50]王爱东.痰热清注射液治疗慢性阻塞性肺疾病急性加重期72例疗效观察[J].医学理论与实践,2011,24(6):664.
[51]张利君.苏子降气汤合三子养亲汤加减治疗慢性阻塞性肺疾病临床疗效观察[J].新中医,2011,43(2):31-32.
[52]贾杰.针刺配合康复训练治疗慢性阻塞性肺病66例[J].陕西中医，2004，25(12)：1125-1127．
[53]张玲.益气扶正汤加针刺治疗慢性阻塞性肺病288例[J].陕西中医,2003,24(10):882-883．
[54]万文蓉.宣散方针灸治疗慢性阻塞性肺疾病36例临床研究[J].光明中医,2007,22(3):40-42．
[55]杨平,张艳玲,彭敏.培土生金针刺法对COPD缓解期患者生活质量的影[J]．辽宁中医药大学学报,2009,1(3):149-150．
[56]宋昱晨.穴位贴敷与卡介苗素注射治疗稳定期慢性阻塞性肺病的疗效和免疫指标对比观察[J].浙江中医杂志,2008,43(8):44l-442．
[57]王玲,李风森,杨卫江.穴位经皮给药对慢性阻塞性肺病患者肺功能影响的研究[J].辽宁中医杂志,2006,33(10):1232-1233．
[58]刘斌，李英姿．中药外敷治疗慢性阻塞性肺病300例[J]．福建中医药，2001，32(6)：25．
[59]姜明全,曹忠良,项志兵,等.参麦注射液合用雾化吸人鱼腥草注射液治疗慢性阻塞性肺病急性加重期疗效观察[J].上海中医药杂志,2006,40(5):11-12．
[60]黄大文,李英姿,刘斌.中药制剂经氧气雾化吸人治疗慢性阻塞性肺病疗效观察[J].陕西中医学院学报,2003,26(4):7-9．
[61]辛瑾琛,谈馨媛,林琳.砭石治疗慢性阻塞性肺疾病急性加蓖期临床研究[J]．中国中医药信息杂志,2008,15(8):14-15．
[62]谭韬,毕番,杨秀萍,等.呼吸气功疗法对慢性阻塞性肺疾病稳定期患者肺康复的疗效研究[J].贵阳中医学院学报,2007,29(6):34-35．
[63]王洪武,孙广仁.寒饮蕴肺证辨证要点临床调查.山西中医,2004,20（3）：41-43
[64]颜乾麟.中医病机理论研究的思考[J].同济大学学报(医学版),2007,28（5）：2
[65]高雪,曲敬来.论“肺阳”与慢性咳喘病的关系［J］.中医药学报,1998,(4):3－4．
[66]万文蓉,卢泰坤论阳虚痰瘀是慢性阻塞性肺疾病的基本病机［J］.中医药学刊，2005,23(9):1672．
[67] Sun SH,Tang WX,Liu C,et al.Effects of tumonecrosis factor alpha onproteolysis of respiratory muscles in rats with chronic obstructivepulmonary diseas[J].Zhonghua Jie He He Hu Xi Za Zhi,2007,30(3):186-191.
[68] Chung K F.Cytokines in chronic obstructive pulmonary disease[J].EurRespir J,2001,18:50-59.
[69] Zheng T,Zhu Z,Wang Z,et al. Inducible targeting of IL-13to the adultlung causes matrix metalloproteinase and cathepsin dependent emphysema[J]. J Clin Invest,2000,106(9):1081-1093.
[70]董三军,等.慢性阻塞性肺疾病稳定期血清白介素4及白介素13水平调查[J].中国误诊学杂志.2010,10(28):7048
[71] Kasaian MT,Miller DK.IL-13as a therapeutic target for respir-atorydisease[J]. Biochem Pharmacol,2008,76(2):147-155.
[72] SHIRAKAWA I,DEICHMANN KA,IZUHARA I,et al. Atopy and asthma:geneticvariants of IL-4and IL-13gene signaling[J].Immunol Today,2000,21:60-64.
[73]商燕,李强.白介素-13与支气管哮喘[J]．国外医学.生理、病理科学与临床分册，2001,3:192-194.
[74] ZHENG T,ZHU Z,WANG Z,et al.Inducible targeting of IL-13to the adult lungcauses matrix metalloproteinase-and cathepsin-dependent emphysema[J].JClin Invest2000,106:1081-1093.
[75] VENKAYYA R,LAM M,WILLKOM M,et al.The Th2lymphocyte products IL-4andIL-13rapidly induce airway hyperresponsiveness through direct effectson resident airway cells[J].Am J Respir Cell Mol Biol,2002,26:202-208.
[76] Kuperman D A, Huang X, Koth L L,et al. Direct effects of IL-13onepithelial cells cause airway hyperreactivity and mucus overproductionin asthma[J]. Nat Med,2002,8(8):885-889.
[77] Takanashi S,et al. Interleukin-10level in sputum is reducedbronchialasthma, COPD and in smokers[J].Eur Respir J,1999,14(2):309-314.
[78] Barnes PJ.Mechanisms in COPD: differences from asthma.Chest,2000,117:105
[79] Segura-Valdez L,Pardo A,Gaxiola M,et al. Upregulation ofgelatinases Aand B,collagenases1and2,and increased paren-chymal cell death in COPD.Chest,2000,117:684.
[80]郭瑞霞,张建敏等.基质金属蛋白酶及其抑制物在慢性阻塞性肺病治疗中的价值[J].中国现代医生,2009,47(26):23
[81]郭瑞,张红梅.COPD患者基质金属蛋白酶-9及其抑制物的表达和调控[J].新医学，2008,39（2）:134-136.
[82]戴丽,吴泰华.全反式维甲酸对COPD大鼠肺组织中基质金属蛋白酶-2,9表达的影响[J].内科急危重症杂志,2007,13(5):239-246.
[83]陈洲平,连亚军,夏建华,等.戊四氮点燃大鼠海马水通道蛋白4和水通道蛋白9的表达[J].郑州大学学报(医学版),2008,43(3):428-431.
[84]关方霞,关玉霞,杨波,等.星形胶质细胞形态学观察在高通量药物筛选水通道蛋白4抑制剂中的应用[J].郑州大学学报(医学版),2006,41(5):870-872.
[85] Verkman AS. Role of aquaporins in lung liquid physiology [J]. RespirPhysiol Neurobiol,2007,159(3):324-330.
[86] Rose MC.Mucins:structUre，function，and role in Pulmonary disease[J].AmJPhy si ol,1992，263:L413-L429
[87] Alimam MZ,Piazza FM,Selby DM,et al.Muc-5/5ac mucin messenger RNA andprotein expression is a marker of goblet cell metaplasia in murineairways[J].AmJ Respir Cell Mol Biol,2000,22(3):253-260
[88] Kirkham S,Sheehan JK,Knight D,el.Heterogeneity of airways mucus:variations in the amounts and glycoforms of the major oligomeric mucinsMUC5AC and MUC5B[J].Biochem J,2002,361(Pt3):537-546
[89]万云鹏,关键,丁晓倩. COPD大鼠肺组织中Muc5ac和IL-13的相关性研究[J].现代生物医学进展,2009,9(21):4089
[90]张蔚等.福莫特罗对哮喘小鼠气道杯状细胞增生及黏蛋白MUC5ac mRNA表达的影响[J].温州医学院学报,2010,40(3):
[91] Boer de ⅤⅤⅠ,Han CM,Schadewijk van A,et al.Expression of epidermalgrowth factors and their receptors in the bronchial epithelium ofsubjects with chronic obstructive pulmonary disease. American Journalof Clinical Pathology,2006,125(2):184-192
[92] Luo BL,Niu BC,Feng JT,et al. Downregulation of secretory leukocyteproteinase inhibitor in chronic obstructive pulmonary disease:the roleof TGF-beta1/smads signaling pathways.Arch Med Res,2008,5,39(4):388-396
[93]孙广仁等.温阳化饮方对寒饮蕴肺证家兔肺通气作用的机理研究[J].上海中医药大学学报,2001,15(1):40-42
[94]张庆祥等.温阳化饮方对哮喘病寒饮蕴肺证大鼠BALF中EOS的影响[J].中医药学刊,2006,24(8):1477-1478
[95]张庆祥等.温阳化饮方对哮喘病寒饮蕴肺证大鼠BALF中IL-4和IFN-γ的影响[J].中国中医基础医学杂志,2006,12(9):672-673
[96] Song Y L，Yang B X，Michael A M，et al. Role of ayuaporin water channelsin pleural fluid dynamics［J］. Am J PhysioL Cell Physiol，2000，279：1744-1750.
[97] Song YL,Yang BX. Michael AM,et al. Role of aquaporin water channels inpleural fluid dynamics[J]. Am J Physiol Cell Physiol，2000l.279:C1744
[98] Borok Z. Verkman AS. Lung edema clearance;20years of progress; invitedreview；role of aquaporin water channels in fluid transport in lung andairways[J].J Appli Physiol,2002.93(6):2199
[99]李波，陈东，王桂芳，等.水通道蛋白1345在内毒素性急性肺损伤小鼠肺组织中的表达[J].第二军医大学学报，2008,29(2):131-133
[100]丛培玮,尚冰,王哲,等.肺气虚模型大鼠肺、肾组织水液代谢相关性的机制研究[J].辽宁中医杂志,2012,39(2):357-359
[101]王晴,刘正娟,马乐,等.水通道蛋白－1在急性肺损伤中的表达及意义［J］.大连医科大学学报,2012,34(1):22-25．
[102]丁建中,张六通,李军川,等.水通道蛋白1、4、5在外燥小鼠肺表达的意义[J].时珍国医国药,2012,23(3):764-765
[103]许银姬,陈远彬,王丽丽,林琳.青天葵对内毒素致急性肺损伤大鼠肺水通道蛋白1和5表达的影响[J].中国中西医结合杂志,2010,30(8):861-865
[104]邓青南,周建龙,郭振辉.清气化痰汤对急性肺损伤小鼠水通道蛋白1表达的影响［J］.中国中医急症,2011,20（1）：77-79.
[105] Hattrup CL,Gendler SJ. Structure and function of the cell surface(tethered) mucins[J].Annu Rev Physiol,2008,70:431-457.
[106] Morcillo EJ, Cortijo J.Mucus and MUC in asthma [J].Curr Opin Pulm Med,2006,12(1):1-6.
[107] Rose MC. Mucins: structure, function, and role in pulmonary diseases[J].Am J Physiol,1992,263(4Pt1):413-429.
[108] MA R, WANG Y, CHENG G, et al. MUC5AC expression up-regulation gobletcell hyperplasia in the airway of patients with chronic obstructivepulmonary disease[J]. Chin Med Sci J,2005,20(3):181-184.
[109]袁兵,但齐琴,赵珊.丙烯醛致大鼠气管和肺损伤中内源性Muc5ac的表达变化[J].四川大学学报(医学版),2010,41(6):994-997.
[110] CARAMORI G, DI GREGORIO C, CARLSTEDT I. Mucin expression in peripheralairways of patients with chronic obstructive pulmonary disease [J].Histopathology,2004,45(5):477-484.
[111] BORCHERS M T, WERT S E, LEIKAUF G D. Acrolein-induced MUC5AC expressionin rat airways [J]. Am J Physiol,1998,274(4Pt1):L573-L581.
[112]李雯,徐永健,张珍祥.慢性阻塞性肺疾病患者气道上皮细胞阿米洛利敏感钠通道mRNA表达水平的研究[J].中华结核和呼吸杂志,2004,27(8):533-536.
[113]李雯,徐永健,魏华平.白介素-4和白介素-6在慢性阻塞性肺病肺组织中的表达[J].中国组织化学与细胞化学杂志,2001,10(4):425-428.
[114] SHAO M X, NAKANAGA T, NADEL J A. Cigarette smoke induces MUC5AC mucinoverproduction via tumor necrosis factor-alpha-converting enzyme inhuman airway epithelial(NCI-H292) cells [J]. Am J Physiol Lung Cell MolPhysiol,2004,287(2):L420-L427.
[115]毛翎,白春学,张敏,等.表皮生长因子受体和黏蛋白在慢性阻塞性肺疾病气道中的表达及意义[J].中华结核和呼吸杂志,2004,27(9):585-588.
[116]王明明,张六通,丁建中,等.外感温燥对BALB/c小鼠气道muc5ac表达的影响[J].时珍国医国药,2011,22(7):1751-1753.
[117]王同生,娄源杰,毛毅敏,孙玉霞. MUC5AC黏蛋白在哮喘大鼠肺组织的表达及红霉素的抗炎机制探讨[J].河南科技大学学报（医学版）,2007,25(1):11-13
[118]周勇,赵玮,宋康,等.椒枝软胶囊对哮喘大鼠Muc5ac mRNA表达的影响[J].中华中医药学刊,2012,30(5):1130-1132.
[119]徐传芹,朱述阳,陈景行,岳刚.罗格列酮对哮喘小鼠气道黏液高分泌的影响[J].实用医学杂志,2008,24(22):3836-3838.
[120]熊本强,李翔,李喜兵,等.水通道蛋白1对气道高反应大鼠粘液高分泌的影响[J].湖南师范大学学报（医学版）,2012,9(1):6-9